LOS ANGELES
It sits in plastic tubs on shelves across America — cheap, unglamorous, about as exciting as flour. But according to a new UCLA study, creatine, the most widely used sports supplement on the planet, may be hiding a second identity: a potential ally in the fight against cancer.
Researchers at UCLA's Jonsson Comprehensive Cancer Center report that creatine supplementation doesn't just fuel muscle contractions — it appears to energize dendritic cells, a critical class of immune cells that act as the body's cancer intelligence unit. These cells capture fragments of tumor cells and hand that information to killer T cells so they know exactly what to attack. In mouse models of melanoma, boosting creatine intake visibly slowed tumor growth.
The findings, published in the journal iScience, come from the lab of Lili Yang, a professor of microbiology, immunology and molecular genetics at UCLA. "What this study shows is that creatine doesn't just help the T cells fighting cancer — it also energizes the entire infrastructure that supports and guides them," Yang said.
The Immune System's Missing Link
Most FDA-approved immunotherapies — checkpoint inhibitors and CAR-T therapies — are laser-focused on killer T cells, the immune system's frontline assassins. The problem is that only 20% to 40% of patients actually respond, leaving a majority without meaningful benefit.
Yang's team zeroed in on dendritic cells — the immune system's scouts and trainers. Killer T cells don't spontaneously know what a tumor looks like. Dendritic cells have to find tumor fragments, process them, and present them to T cells. If dendritic cells are sluggish, even healthy T cells have nothing to go on.
That's where creatine comes in. The compound is best known for regenerating ATP — the energy currency that powers cells. Yang's team suspected that same energy boost that helps a bicep power through a final rep might also help dendritic cells power through the energy-intensive process of presenting tumor antigens. Their data suggests they were right.
What the Experiments Showed
Researchers gave daily creatine to mice implanted with melanoma tumors. The creatine-supplemented mice showed significantly slower tumor growth compared to untreated controls. When they examined the tumor tissue, they found not just more dendritic cells inside the tumors, but dendritic cells that were more active — more engaged in capturing tumor material and activating nearby T cells.
The team then extended the work into human cells, which echoed the mouse results. Because most immunotherapy research has focused on juicing up T cells themselves, the idea of strengthening the "coaching staff" that trains those T cells represents a genuinely different angle of attack.
Why Scientists Are Excited — and Why You Shouldn't Stock Up Yet
It's worth being blunt: this is not a clinical trial. It was not conducted in cancer patients. It does not prove that taking creatine will help treat or prevent cancer in humans. The researchers have been careful to say so.
That caveat matters. Creatine is one of the most extensively studied supplements in sports science, generally regarded as safe for healthy adults. But cancer patients are not the same population that has been safety-tested, particularly those undergoing treatments that stress the kidneys and liver — the organs responsible for processing creatine. Doctors have stressed that anyone currently undergoing cancer treatment should talk to their oncologist before adding any supplement.
Still, the appeal is obvious. Unlike most emerging cancer therapies — with six- or seven-figure costs and years of regulatory review — creatine costs pennies per dose, is sold over the counter, and has decades of safety data behind it. If future research confirms even a modest immune-boosting benefit, it could represent one of the cheapest adjuncts to immunotherapy ever discovered.
Expert Perspective
Yang and her colleagues have framed the discovery as a launching point. Her lab's research focuses on why immunotherapy works for some patients and poorly for others — and dendritic cell function has emerged as a promising, understudied piece of that puzzle. By showing that a widely available compound can measurably change dendritic cell behavior, the study hands researchers a concrete, testable mechanism.
Other tumor immunology researchers have long suspected that metabolic support for immune cells — ensuring they have enough cellular fuel — could improve immunotherapy outcomes. This study adds hard data to that theory. The next step is testing whether creatine can be safely combined with existing therapies in animal models before any human trials can be designed.
What This Means for You
If you're a healthy adult who already takes creatine for the gym, this study doesn't change your safety profile — creatine's track record there is well established. What it does offer is a new reason to pay attention: for the 60% to 80% of cancer patients who don't respond to T-cell-based immunotherapies, an eventual creatine-based add-on — if validated — could represent a low-cost way to widen the pool of patients who benefit.
For now, the most important takeaway is patience paired with a conversation. This is early-stage, preclinical science — exciting to researchers, but still several steps removed from anything an oncologist would prescribe. Anyone in treatment who is curious about creatine should raise it with their care team rather than adding it on their own.
The Bottom Line
The supplement aisle and the oncology ward don't often overlap, but UCLA's new research has drawn an unexpected line between them. Creatine isn't a cancer treatment — not yet, and maybe not ever, pending years of additional study. But by showing that a $15 tub of powder can energize the immune cells responsible for training the body's cancer killers, Yang's team has handed researchers a cheap, safe, already-available compound with a plausible new job to do. For the millions of patients who don't respond to today's immunotherapies, that's a lead worth chasing.
Sources: UCLA, iScience, Jonsson Comprehensive Cancer Center
